These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
949 related articles for article (PubMed ID: 16398057)
41. Transient receptor potential channels in rat renal microcirculation: actions of angiotensin II. Takenaka T; Suzuki H; Okada H; Inoue T; Kanno Y; Ozawa Y; Hayashi K; Saruta T Kidney Int; 2002 Aug; 62(2):558-65. PubMed ID: 12110018 [TBL] [Abstract][Full Text] [Related]
42. Divergent natriuretic action of calcium channel antagonists in mongrel dogs: renal haemodynamics as a determinant of natriuresis. Honda M; Hayashi K; Matsuda H; Kubota E; Tokuyama H; Okubo K; Ozawa Y; Saruta T Clin Sci (Lond); 2001 Oct; 101(4):421-7. PubMed ID: 11566080 [TBL] [Abstract][Full Text] [Related]
43. Fast activation of dihydropyridine-sensitive calcium channels of skeletal muscle. Multiple pathways of channel gating. Ma J; González A; Chen R J Gen Physiol; 1996 Sep; 108(3):221-32. PubMed ID: 8882865 [TBL] [Abstract][Full Text] [Related]
44. Development of newer calcium channel antagonists: therapeutic potential of efonidipine in preventing electrical remodelling during atrial fibrillation. Ohashi N; Mitamura H; Ogawa S Drugs; 2009; 69(1):21-30. PubMed ID: 19192934 [TBL] [Abstract][Full Text] [Related]
45. Effects of manidipine hydrochloride on the renal microcirculation in spontaneously hypertensive rats. Tojo A; Kimura K; Matsuoka H; Sugimoto T J Cardiovasc Pharmacol; 1992 Dec; 20(6):895-9. PubMed ID: 1282591 [TBL] [Abstract][Full Text] [Related]
46. [Pleiotropic effects of new generation calcium channel blockers on cardiovascular protections]. Ogimoto A; Higaki J Clin Calcium; 2013 Apr; 23(4):569-74. PubMed ID: 23545747 [TBL] [Abstract][Full Text] [Related]
48. [Calcium antagonists: current and future applications based on new evidence. Renal protective action of calcium channel blockers]. Kimura G Clin Calcium; 2010 Jan; 20(1):94-9. PubMed ID: 20048440 [TBL] [Abstract][Full Text] [Related]
49. [Role of calcium antagonists in the treatment of arterial hypertension]. Velasco M; Negrín C Invest Clin; 1997 Nov; 38 Suppl 2():65-72. PubMed ID: 9471233 [TBL] [Abstract][Full Text] [Related]
50. T-type Ca channel blockade as a determinant of kidney protection. Hayashi K; Homma K; Wakino S; Tokuyama H; Sugano N; Saruta T; Itoh H Keio J Med; 2010; 59(3):84-95. PubMed ID: 20881449 [TBL] [Abstract][Full Text] [Related]
51. Identification of L- and T-type Ca2+ channels in rat cerebral arteries: role in myogenic tone development. Abd El-Rahman RR; Harraz OF; Brett SE; Anfinogenova Y; Mufti RE; Goldman D; Welsh DG Am J Physiol Heart Circ Physiol; 2013 Jan; 304(1):H58-71. PubMed ID: 23103495 [TBL] [Abstract][Full Text] [Related]
52. Excitation-contraction coupling in cardiac and vascular smooth muscle: modification by calcium-entry blockade. McCall D Circulation; 1987 Jun; 75(6 Pt 2):V3-14. PubMed ID: 2436829 [TBL] [Abstract][Full Text] [Related]
53. Nitric oxide synthase inhibition activates L- and T-type Ca2+ channels in afferent and efferent arterioles. Feng MG; Navar LG Am J Physiol Renal Physiol; 2006 Apr; 290(4):F873-9. PubMed ID: 16263803 [TBL] [Abstract][Full Text] [Related]
54. Isoform-specific inhibition of L-type calcium channels by dihydropyridines is independent of isoform-specific gating properties. Hu H; Marban E Mol Pharmacol; 1998 May; 53(5):902-7. PubMed ID: 9584217 [TBL] [Abstract][Full Text] [Related]
55. Dihydropyridine-insensitive calcium currents contribute to function of small cerebral arteries. Kuo IY; Ellis A; Seymour VA; Sandow SL; Hill CE J Cereb Blood Flow Metab; 2010 Jun; 30(6):1226-39. PubMed ID: 20125181 [TBL] [Abstract][Full Text] [Related]
56. Calcium channel antagonists and human immunodeficiency virus coat protein-mediated neuronal injury. Lipton SA Ann Neurol; 1991 Jul; 30(1):110-4. PubMed ID: 1656845 [TBL] [Abstract][Full Text] [Related]
57. Role of voltage-gated calcium channels in potassium-stimulated aldosterone secretion from rat adrenal zona glomerulosa cells. Uebele VN; Nuss CE; Renger JJ; Connolly TM J Steroid Biochem Mol Biol; 2004 Oct; 92(3):209-18. PubMed ID: 15555914 [TBL] [Abstract][Full Text] [Related]
58. Efonidipine reduces proteinuria and plasma aldosterone in patients with chronic glomerulonephritis. Ishimitsu T; Kameda T; Akashiba A; Takahashi T; Ohta S; Yoshii M; Minami J; Ono H; Numabe A; Matsuoka H Hypertens Res; 2007 Jul; 30(7):621-6. PubMed ID: 17785930 [TBL] [Abstract][Full Text] [Related]
59. Evaluation of the inhibitory effect of dihydropyridines on N-type calcium channel by virtual three-dimensional pharmacophore modeling. Ogihara T; Kano T; Kakinuma C Arzneimittelforschung; 2009; 59(6):283-8. PubMed ID: 19634509 [TBL] [Abstract][Full Text] [Related]
60. Renal and vascular protective effects of cilnidipine in patients with essential hypertension. Morimoto S; Yano Y; Maki K; Iwasaka T J Hypertens; 2007 Oct; 25(10):2178-83. PubMed ID: 17885563 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]